A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

Background: It has been proposed that treatments for irritable bowel syndrome with constipation (IBS-C) should provide rapid symptomatic relief, be intermittent, and effective upon repeated use. Aims: To evaluate the efficacy and safety of tegaserod on IBS symptoms, and its impact on quality of life...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2005-12, Vol.54 (12), p.1707-1713
Hauptverfasser:	Tack, J, Müller-Lissner, S, Bytzer, P, Corinaldesi, R, Chang, L, Viegas, A, Schnekenbuehl, S, Dunger-Baldauf, C, Rueegg, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdomen Adolescent Adult Aged Biological and medical sciences CHMP Clinical trials Committee for Medicinal Products for Human Use Constipation Constipation - drug therapy Constipation - rehabilitation Double-Blind Method Drug Administration Schedule efficacy Efficiency Female Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal Agents - adverse effects Gastrointestinal Agents - therapeutic use Humans IBS-C IBS-C women Indoles - adverse effects Indoles - therapeutic use Irritable bowel syndrome Irritable Bowel Syndrome - drug therapy Irritable Bowel Syndrome - rehabilitation irritable bowel syndrome with constipation Laxatives Medical sciences Middle Aged Neurogastroenterology Other diseases. Semiology Pain Patient Satisfaction Prospective Studies QoL Quality of Life repeated treatment safety Serotonin Receptor Agonists - adverse effects Serotonin Receptor Agonists - therapeutic use Stomach. Duodenum. Small intestine. Colon. Rectum. Anus tegaserod TFI treatment free interval Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!